![](/img/cover-not-exists.png)
Time to relapse after tildrakizumab withdrawal in patients with moderateâtoâsevere psoriasis who were responders at week 28: postâhoc analysis through 64 weeks from reSURFACE 1 trial
Warren, R.B., Carrascosa, J.M., Fumero, E., Schoenenberger, A., Lebwohl, M.G., Szepietowski, J.C., Reich, K.Journal:
Journal of the European Academy of Dermatology and Venereology
DOI:
10.1111/jdv.16964
Date:
September, 2020
File:
PDF, 1.01 MB
2020